

CHEMBIO DIAGNOSTICS, INC.  
Form 8-K  
November 19, 2007

---

---

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 19, 2007 (November 13, 2007)

**CHEMBIO DIAGNOSTICS, INC.**

(Exact name of registrant as specified in its charter)

<b>Nevada</b> (State or other jurisdiction of Incorporation)	<b>0-30379</b> (Commission File Number)	<b>88-0425691</b> (IRS Employer Identification Number)
	<b>3661 Horseblock Road</b> <b>Medford, NY 11763</b> (Address of principal executive offices)	
	<b>631-924-1135</b> (Registrant's Telephone Number)	

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 3.02. Unregistered Sales of Equity Securities**

On November 13, 2007, as payment of dividends on the Series A Preferred Stock, Chembio Diagnostics, Inc. (the "Company") issued 237,010 shares of common stock to holders of the series A preferred stock. No cash was exchanged in this issuance.

The dividends were issued in connection with the Company's sale of Series A Preferred Stock in May 2004, which was exempt from registration under the Securities Act of 1933, as amended (the "Securities Act") and applicable state laws pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D. These issuances qualified for exemption from registration because (i) the securities were purchased by accredited investors only; (ii) the Company did not engage in any general solicitation or advertising to market the securities; (iii) each purchaser was provided the opportunity to ask questions and receive answers from the Company regarding the offering; and (iv) the purchasers received "restricted securities."

**ITEM 7.01. Regulation FD Disclosure**

The date for the voting period has been extended, from November 20, 2007 to December 12, 2007, on the proposed amendments to the governing documents for the Series A, B and C preferred stock and for certain warrants and options. A description of these proposed amendments was previously reported on the Form 8-K that was filed on October 19, 2007.

\* \* \* \* \*

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 19, 2007

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert  
Lawrence A. Siebert  
Chief Executive Officer